within Pharmacolibrary.Drugs.ATC.N;

model N05AF04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 5.555555555555555e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>ATC code:</td><td>N05AF04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tiotixene is a typical antipsychotic medication of the thioxanthene class, primarily used in the management of schizophrenia. It works mainly as a dopamine D2 receptor antagonist, with some activity as an antagonist at other receptors such as serotonin and histamine. Tiotixene has been used since the 1960s and is still approved for antipsychotic therapy in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults with schizophrenia (typical clinical population), as no direct published PK study data are available.</p><h4>References</h4><ol><li><p>Ereshefsky, L, et al., &amp; Jann, MW (1991). Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. <i>Journal of clinical psychopharmacology</i> 11(5) 296â€“301. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1765572/\">https://pubmed.ncbi.nlm.nih.gov/1765572</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end N05AF04;
